Related Experiment Video
Updated: May 12, 2025
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
Pathology of Chronic Kidney Disease and Spatial Metabolomics
Jeffrey B Hodgin1, Soumya Maity2, Matthias Kretzler3
1Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI.
Insights
Spatial metabolomics can reveal molecular drivers of chronic kidney disease (CKD) pathology. This technology helps characterize cellular programs and pathways underlying CKD progression, improving understanding of kidney disease.
Area of Science:
- Nephrology
- Molecular Biology
- Pathology
Background:
- Chronic kidney disease (CKD) presents with common pathologic features like glomerular sclerosis, tubular atrophy, interstitial fibrosis, inflammation, and vascular rarefaction.
- Despite decades of description, the underlying molecular drivers of these CKD pathologic features remain poorly understood.
Purpose of the Study:
- To review the potential of spatial metabolomics as a critical technology for characterizing shared cellular programs in CKD.
- To discuss approaches and challenges in developing spatial metabolomics signatures for CKD pathologic features.
Main Methods:
- Review of existing literature on CKD pathology, multiomics, spatial biology, and metabolomics.
- Discussion of the application of spatial metabolomics platforms to identify molecular drivers in kidney disease.
Main Results:
- Spatial metabolomics offers a promising approach to capture protective and destructive pathways in CKD.
- Development of spatial metabolomics signatures can aid in understanding the molecular basis of CKD progression.
Conclusions:
- Spatial metabolomics is a key technology for dissecting the molecular underpinnings of CKD pathology.
- Further development and application of spatial metabolomics are crucial for advancing CKD research and therapeutic strategies.
Abstract:
Chronic kidney disease (CKD) has diverse etiologies but exhibits common features in presentation and progression. These include glomerular sclerosis, tubular atrophy, and interstitial fibrosis, often with inflammation and vascular rarefaction. Although these pathologic features have been described in CKD for decades, the molecular drivers of the disease process remain poorly understood. In the era of multiomics and spatial biology, the spatial metabolomics platform could well be a critical technology to guide characterization of the shared cellular programs, capturing the important protective and destructive pathways that ultimately culminate in each of these pathologic features. In this review, we discuss the specific approaches and challenges to developing spatial metabolomics signatures for pathologic features in CKD.
Related Concept Videos
01:45Kidney Structure
01:10Nephrons